• Homepage
• About us
• Our Partners
• Research database
• Workshops
• Newsletters and resources
• Videos and Animations
• International Conferences
• Funding opportunities
• Search

I have experience with the use of brain microdialysis, pharmacokinetic analysis, and utilization of preclinical models to study central nervous system (CNS) pharmacology. I lead collaborative preclinical and clinical studies focused on understanding blood-brain barrier integrity in normal brain and malignant gliomas with an effort to develop novel treatment strategies for patients with brain tumors. 

Existing collaborations relevant to drug delivery

N/A

Publications relevant to drug delivery

Jackson S, Weingart J, Nduom EK, Harfi TT, George RT, McAreavey D, Ye X, Anders NM, Peer C, Figg WD, Gilbert M, Rudek MA, Grossman SA. The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS. 2018 Jan 15;15(1):2. doi: 10.1186/s12987-017-0088-8.

McCord M, Mukouyama YS, Gilbert MR, Jackson S. Targeting WNT Signaling for Multifaceted Glioblastoma Therapy. Front Cell Neurosci. 2017 Oct 13;11:318. doi: 10.3389/fncel.2017.00318. eCollection 2017. Review.

Jackson S, ElAli A, Virgintino D, Gilbert MR. Blood-brain barrier pericyte importance in malignant gliomas: what we can learn from stroke and Alzheimer's disease. Neuro Oncol. 2017 Sep 1;19(9):1173-1182. doi: 10.1093/neuonc/nox058.

Jackson S, George RT, Lodge MA, Piotrowski A, Wahl RL, Gujar SK, Grossman SA. The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study. J Neurooncol. 2017 May;132(3):513-519. doi: 10.1007/s11060-017-2404-1. Epub 2017 Mar 17.

Naidoo J, Panday H, Jackson S, Grossman SA.  Optimizing the Delivery of Antineoplastic Therapies to the Central Nervous System.  Oncology (Williston Park). 2016 Nov 15;30(11):953-962. Review.

Jackson S, Anders NM, Mangraviti A, Wanjiku TM, Sankey EW, Liu A, Brem H, Tyler B, Rudek MA, Grossman SA. The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. J Neurooncol. 2016 Feb;126(3):433-439. doi: 10.1007/s11060-015-1998-4. Epub 2015 Dec 1.

Morfouace M, Cheepala S, Jackson S, Fukuda Y, Patel YT, Fatima S, Kawauchi D, Shelat AA, Stewart CF, Sorrentino BP, Schuetz JD, Roussel MF.  ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy.  Cancer Res. 2015 Sep 15;75(18):3879-3889. doi: 10.1158/0008-5472.CAN-15-0030. Epub 2015 Jul 21.

Rodriguez FJ, Tihan T, Lin D, McDonald W, Nigro J, Feuerstein B, Jackson S, Cohen K, Burger PC.  Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients.  Am J Surg Pathol. 2014 Aug;38(8):1058-1070. doi: 10.1097/PAS.0000000000000221.

Jackson S, Patay Z, Howarth R, Pai Panandiker AS, Onar-Thomas A, Gajjar A, Broniscer A.  Clinico-radiologic characteristics of long-term survivors of diffuse intrinsic pontine glioma. J Neurooncol. 2013 Sep;114(3):339-344. doi: 10.1007/s11060-013-1189-0. Epub 2013 Jun 29.